Literature DB >> 18638424

In perspective: murine models of scleroderma.

Minghua Wu1, John Varga.   

Abstract

An understanding of the complex pathogenesis of systemic sclerosis (SSc) has been slow to emerge, due in large part to the lack of an animal model recapitulating the three cardinal attributes of SSc: autoimmunity, vasculopathy, and fibrosis. Experimental manipulations in inbred murine strains can lead to conditions that mimic SSc fibrosis. Furthermore, genetic engineering has enabled the creation of novel murine strains that spontaneously develop fibrosis or are protected from fibrosis development. Studies of these mice shed light on the cell types, cell interactions, molecules, and pathways that contribute to SSc manifestations. High-throughput discovery technologies such as DNA microarrays in animal models can identify novel genes and regulatory networks that are important for disease manifestations and that may be targets for therapy. In this brief review, we highlight recent progress in the field and attempt to place the strengths and limitations of popular SSc murine models in perspective.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18638424     DOI: 10.1007/s11926-008-0030-9

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  55 in total

1.  Animal models of pulmonary fibrosis: how far from effective reality?

Authors:  Jack Gauldie; Martin Kolb
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2007-12-21       Impact factor: 5.464

2.  Adenosine A2A receptors in diffuse dermal fibrosis: pathogenic role in human dermal fibroblasts and in a murine model of scleroderma.

Authors:  E S L Chan; P Fernandez; A A Merchant; M C Montesinos; S Trzaska; A Desai; C F Tung; D N Khoa; M H Pillinger; A B Reiss; M Tomic-Canic; J F Chen; M A Schwarzschild; B N Cronstein
Journal:  Arthritis Rheum       Date:  2006-08

3.  Fibroblast-specific expression of a kinase-deficient type II transforming growth factor beta (TGFbeta) receptor leads to paradoxical activation of TGFbeta signaling pathways with fibrosis in transgenic mice.

Authors:  Christopher P Denton; Bing Zheng; Lowri A Evans; Xu Shi-wen; Voon H Ong; Ivan Fisher; Konstantinos Lazaridis; David J Abraham; Carol M Black; Benoit de Crombrugghe
Journal:  J Biol Chem       Date:  2003-04-21       Impact factor: 5.157

4.  Relaxin deficiency in mice is associated with an age-related progression of pulmonary fibrosis.

Authors:  Chrishan S Samuel; Chongxin Zhao; Ross A D Bathgate; Courtney P Bond; Matthew D Burton; Laura J Parry; Roger J Summers; Mimi L K Tang; Edward P Amento; Geoffrey W Tregear
Journal:  FASEB J       Date:  2002-11-01       Impact factor: 5.191

Review 5.  Murine models of pulmonary fibrosis.

Authors:  Bethany B Moore; Cory M Hogaboam
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2007-11-09       Impact factor: 5.464

6.  The tight skin 2 mouse. An animal model of scleroderma displaying cutaneous fibrosis and mononuclear cell infiltration.

Authors:  P J Christner; J Peters; D Hawkins; L D Siracusa; S A Jiménez
Journal:  Arthritis Rheum       Date:  1995-12

7.  Impairment of the antifibrotic effect of hepatocyte growth factor in lung fibroblasts from African Americans: possible role in systemic sclerosis.

Authors:  Galina S Bogatkevich; Anna Ludwicka-Bradley; Kristin B Highland; Faye Hant; Paul J Nietert; C Beth Singleton; Carol A Feghali-Bostwick; Richard M Silver
Journal:  Arthritis Rheum       Date:  2007-07

8.  Role of monocyte chemoattractant protein-1 and its receptor,CCR-2, in the pathogenesis of bleomycin-induced scleroderma.

Authors:  Toshiyuki Yamamoto; Kiyoshi Nishioka
Journal:  J Invest Dermatol       Date:  2003-09       Impact factor: 8.551

9.  Systemic and cell type-specific gene expression patterns in scleroderma skin.

Authors:  Michael L Whitfield; Deborah R Finlay; John Isaac Murray; Olga G Troyanskaya; Jen-Tsan Chi; Alexander Pergamenschikov; Timothy H McCalmont; Patrick O Brown; David Botstein; M Kari Connolly
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-06       Impact factor: 11.205

10.  Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.

Authors:  Moisés Selman; Guillermo Carrillo; Andrea Estrada; Mayra Mejia; Carina Becerril; José Cisneros; Miguel Gaxiola; Rogelio Pérez-Padilla; Carmen Navarro; Thomas Richards; James Dauber; Talmadge E King; Annie Pardo; Naftali Kaminski
Journal:  PLoS One       Date:  2007-05-30       Impact factor: 3.240

View more
  17 in total

1.  The early growth response gene Egr2 (Alias Krox20) is a novel transcriptional target of transforming growth factor-β that is up-regulated in systemic sclerosis and mediates profibrotic responses.

Authors:  Feng Fang; Kohtaro Ooka; Swati Bhattacharyya; Swati Bhattachyya; Jun Wei; Minghua Wu; Pan Du; Simon Lin; Francesco Del Galdo; Carol A Feghali-Bostwick; John Varga
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

Review 2.  Early growth response transcription factors: key mediators of fibrosis and novel targets for anti-fibrotic therapy.

Authors:  Swati Bhattacharyya; Minghua Wu; Feng Fang; Warren Tourtellotte; Carol Feghali-Bostwick; John Varga
Journal:  Matrix Biol       Date:  2011-04-13       Impact factor: 11.583

3.  Canonical Wnt signaling induces skin fibrosis and subcutaneous lipoatrophy: a novel mouse model for scleroderma?

Authors:  Jun Wei; Denisa Melichian; Kazuhiro Komura; Monique Hinchcliff; Anna P Lam; Robert Lafyatis; Cara J Gottardi; Ormond A MacDougald; John Varga
Journal:  Arthritis Rheum       Date:  2011-06

4.  Early growth response 3 (Egr-3) is induced by transforming growth factor-β and regulates fibrogenic responses.

Authors:  Feng Fang; Anna J Shangguan; Kathleen Kelly; Jun Wei; Katherine Gruner; Boping Ye; Wenxia Wang; Swati Bhattacharyya; Monique E Hinchcliff; Warren G Tourtellotte; John Varga
Journal:  Am J Pathol       Date:  2013-07-30       Impact factor: 4.307

Review 5.  Animal models of scleroderma: current state and recent development.

Authors:  Yoshihide Asano; Shinichi Sato
Journal:  Curr Rheumatol Rep       Date:  2013-12       Impact factor: 4.592

Review 6.  Double heterozygous mice for Klf5 and Fli1 genes: a new animal model of systemic sclerosis recapitulating its three cardinal pathological features.

Authors:  Yoshihide Asano
Journal:  Med Mol Morphol       Date:  2015-05-19       Impact factor: 2.309

7.  Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma.

Authors:  Minghua Wu; Denisa S Melichian; Eric Chang; Matthew Warner-Blankenship; Asish K Ghosh; John Varga
Journal:  Am J Pathol       Date:  2009-01-15       Impact factor: 4.307

8.  Essential roles for early growth response transcription factor Egr-1 in tissue fibrosis and wound healing.

Authors:  Minghua Wu; Denisa S Melichian; Mauricio de la Garza; Katherine Gruner; Swati Bhattacharyya; Luke Barr; Aisha Nair; Shiva Shahrara; Peter H S Sporn; Thomas A Mustoe; Warren G Tourtellotte; John Varga
Journal:  Am J Pathol       Date:  2009-08-13       Impact factor: 4.307

Review 9.  Transforming growth factor beta as a therapeutic target in systemic sclerosis.

Authors:  John Varga; Boris Pasche
Journal:  Nat Rev Rheumatol       Date:  2009-04       Impact factor: 20.543

10.  Connective tissue growth factor is induced in bleomycin-induced skin scleroderma.

Authors:  Shangxi Liu; Reza Taghavi; Andrew Leask
Journal:  J Cell Commun Signal       Date:  2009-11-15       Impact factor: 5.782

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.